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The type I interferons (IFNs), IFNb and various IFNas, are pleiotropic cytokines acting on a range of cell types and eliciting a diverse range of responses. For many years IFNb was thought to be a potential agent for the treatment of a variety of immunemediated diseases. Clinical trials showing a beneficial effect of IFNb treatment on clinical and MRI measures in relapsingremitting multiple sclerosis were published almost a decade ago. 1 2 These publications have stimulated studies on its potential for the treatment of patients with rheumatoid arthritis (RA). IFNb has clear anti-inflammatory properties 3 and plays an important role in bone homeostasis. 4 Of special interest is the ability of IFNb to reduce the secretion of proinflammatory mediators such as interleukin (IL)6, tumour necrosis factor (TNF)a, matrix metalloproteinases (MMPs) and prostaglandin E2, which are key players in the pathogenesis of RA. 5 6 In addition, IFNb has antiangiogenic properties, 7 which could boost therapeutic effect in RA. 8 The notion that IFNb treatment may reduce arthritis is supported by animal experiments. Several studies examining the effect of IFNb in collagen-induced arthritis (CIA) in mice have been published. In one study mice were given daily intraperitoneal injections with mouse IFNb 9 and in another study, mice were injected intraperitoneally with a single injection of fibroblasts expressing IFNb, resulting in continuous IFNb production. 10 Both studies revealed a beneficial effect on arthritis activity and histological scores for inflammation. A similar effect was shown in CIA in rhesus monkeys that were treated daily for 7 days with recombinant human IFNb. 11 More recently, it has been shown that IFNb-deficient mice had prolonged CIA with a higher incidence of arthritis compared to control mice, 12 supporting the evidence that IFNb has an anti-inflammatory effect.
Based on the favourable effects of daily treatment with relatively high dosages of IFNb in animal models of RA, we previously performed an open label phase I study in 12 patients with active RA who were treated with purified natural fibroblast IFNb, 11 followed by a double-blind, placebo-controlled phase II trial that evaluated the efficacy of mammalian cellderived recombinant IFNb1a. 13 In the first, open study there were trends towards clinical improvement, although there was no change in key synovial biomarkers.
14 In the latter study 209 patients with RA who were on stable methotrexate received 2.2 or 44 mg IFNb1a, or placebo, subcutaneously three times weekly for a period of 24 weeks. 13 It was felt that daily injections with higher dosages, comparable to those used in the animal models, would not be tolerated by the patients. This dosing regimen did not result in clinical improvement or protection against joint destruction, 13 perhaps because higher and more constant levels of IFNb may be required to translate into clinical benefit. 3 Novel approaches are under investigation using IFNb as a therapeutic agent. Two different strategies are being evaluated: (1) systemic combination therapy of low dosage IFNb treatment with inhibition of the IkB kinase (IKK)-related kinase, IKKe and (2) intra-articular gene therapy aimed at reaching relatively high levels of IFNb at the site of inflammation, thus limiting systemic side effects. The interesting study by Corr et al (see page 257) in this issue of the Annals of the Rheumatic Diseases 15 examined the role of IKKe in the K/BxN serum model of RA and its ability to improve the response to systemic IFNb therapy. IKKe is constitutively expressed in synovial tissue of patients with RA and significantly higher levels of phosphorylated IKKe were observed in RA synovium compared to osteoarthritis. 16 IKKe is an IKK-related kinase with 30% homology to IKK1 and IKK2, and was first described as a lipopolysaccharide (LPS)-inducible kinase. 17 Recent work has suggested that the primary role of IKKe may be the phosphorylation of interferon regulatory factor 3 (IRF3), 18 leading to the induction of type I interferons. In addition, IKKe may induce the expression of several MMPs and chemokines, suggesting that IKKe might be a good target to suppress synovial inflammation. 19 Corr et al showed that either IKKe deficiency or low dose IFNb treatment in wild type mice protects in part against inflammation in the passive serum transfer model of RA. There was a statistically significant decrease in arthritis activity in IFNbtreated mice and IFNa/b receptor-deficient mice had an accentuated course of arthritis, consistent with the studies evaluating the role of IFNb in arthritis discussed above. Of interest, the potential benefit of combination therapy was suggested by the observation that low dose IFNb treatment in IKKe-deficient mice resulted in a further reduction of arthritis scores. This combination therapy could enhance efficacy and decrease the suppressive effects of IKKe inhibition on host defence. Thus, combination therapy comprising low dose IFNb treatment and IKKe inhibition may perhaps offer a new treatment option for patients with RA. An overview of the proposed mechanisms of action is shown in fig 1. The study by Corr et al does not only present very interesting scientific data on IFN-regulated mechanisms, but it also provides the rationale for more comprehensive preclinical studies on the effects of coadministration of IFNb with an IKKe inhibitor. However, an important question will be if systematic treatment with even low dosages of IFNb will be tolerated by patients with RA. In our previous clinical trial we observed a trend towards increased injection site reactions (13%), flu-like symptoms (18%) and fever (6%) in the group that received very low IFNb dosages (2.2 mg three times weekly) compared to matching placebo (3%, 12% and 0%, respectively). 12 In light of the potential side effects of systemic treatment, an alternative might be the development of intra-articular treatment. We have previously hypothesised that continuous therapeutic levels of IFNb local at the site of inflammation may be required to induce clinical efficacy and to avoid systemic side effects. 3 This could be achieved by local gene therapy of the inflamed joint. Recombinant adenoassociated (rAAV) vectors are currently considered as the most optimal vectors for the treatment of immune-mediated inflammatory diseases, including RA, because of their high safety profile together with the capacity to confer long-term expression of therapeutic transgenes in a variety of tissues. 20 We have identified rAAV serotype 5 as the most efficient rAAV vector for transducing synovial tissue. 21 22 After successful proof of concept studies, using an adenoviral vector (Ad), 23 we have investigated the potential of intra-articular IFNb gene therapy using an rAAV5 vector expressing rat IFNb in adjuvant-induced arthritis in rats. 24 Local delivery of Ad or rAAV5 vectors expressing rat IFNb in the ankle joint after the onset of disease reduced paw swelling impressively in treated and untreated contralateral joints. Strikingly, IFNb treatment also protected against bone erosions and cartilage degradation. 
